Table 2.

Characteristics of the cohort and groups

	Cohorta		WPa		BPa,c
	n	%	n	%	n	%
Patients eligible for analysis	162	100	47	29	115	71
Age median (range)	60	30–86	61	36–83	58	30–86
Age <60	88	50.8	21	46b	67	58b
HLA-A2 positive	92	57	47	100	45	40
Surgical staging
I a, b, c	38	23	0	0	38 (22)	33
II a, b, c	17	10	0	0	15 (9)	13
III a, b, c	82	51	32	68	52 (9)	45
IV	25	15	15	32	10 (5)	9
Stage merged
A	53	33	0	0	53 (31)	46
B	109	67	47	100	62 (14)	54
Histopathology
Serous	87	52	47	100	40 (6d)	35
Endometrioid	45	28	0	0	45 (24)	39
Mucinous	14	9	0	0	14 (7)	12
Clear cells	10	6	0	0	10 (7)	9
Others (mixed epithelial, undifferentiated)	6	5	0	0	6 (1)	5
Grade
1	21	13	1	2	20 (11)	17
2	34	21	10	21	24 (12)	21
3	103	63	35	75	68 (21)	59
Unknown	4	3	1	2	3 (1)	3
Treatments
Primary surgery	138	85	35	76	103	89
Radical surgery	55	34	4	9	51	44
Secondary surgery	22	14	8	17	14	12
Platinum-based chemotherapy	152	94	45	97	107	92
Number of chemotherapy cycles
6 and less	97	60	15	33	82	71
More than 6	65	40	31	67	34	29
Radiotherapy	7	4	3	7	4	3

^aCohort: all patients included in the study. WP worst prognosis group, BP better prognosis group

^bDifference in % between WP and BP is NS

^cHLA-A02* genotype in parantheses

^dHLA-A02* genotype patients: 4 in stage I and 2 in stage II